India · Delayed Price · Currency is INR Concord Biotech Statistics
Total Valuation
Concord Biotech has a market cap or net worth of INR 134.29 billion. The enterprise value is 129.97 billion.
| Market Cap | 134.29B |
| Enterprise Value | 129.97B |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | Jul 24, 2026 |
Share Statistics
Concord Biotech has 104.62 million shares outstanding.
| Current Share Class | 104.62M |
| Shares Outstanding | 104.62M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -1.03% |
| Owned by Insiders (%) | 60.87% |
| Owned by Institutions (%) | 15.37% |
| Float | 26.62M |
Valuation Ratios
The trailing PE ratio is 51.47 and the forward PE ratio is 39.98. Concord Biotech's PEG ratio is 2.25.
| PE Ratio | 51.47 |
| Forward PE | 39.98 |
| PS Ratio | 12.73 |
| PB Ratio | 6.66 |
| P/TBV Ratio | 6.66 |
| P/FCF Ratio | 78.20 |
| P/OCF Ratio | 50.32 |
| PEG Ratio | 2.25 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 34.05, with an EV/FCF ratio of 75.68.
| EV / Earnings | 49.82 |
| EV / Sales | 12.32 |
| EV / EBITDA | 34.05 |
| EV / EBIT | 42.31 |
| EV / FCF | 75.68 |
Financial Position
The company has a current ratio of 7.39, with a Debt / Equity ratio of 0.00.
| Current Ratio | 7.39 |
| Quick Ratio | 5.34 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 1,074.49 |
Financial Efficiency
Return on equity (ROE) is 13.54% and return on invested capital (ROIC) is 14.85%.
| Return on Equity (ROE) | 13.54% |
| Return on Assets (ROA) | 8.91% |
| Return on Invested Capital (ROIC) | 14.85% |
| Return on Capital Employed (ROCE) | 14.73% |
| Weighted Average Cost of Capital (WACC) | 6.57% |
| Revenue Per Employee | 6.50M |
| Profits Per Employee | 1.61M |
| Employee Count | 1,624 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.34 |
Taxes
In the past 12 months, Concord Biotech has paid 854.18 million in taxes.
| Income Tax | 854.18M |
| Effective Tax Rate | 24.78% |
Stock Price Statistics
The stock price has decreased by -33.58% in the last 52 weeks. The beta is 0.42, so Concord Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -33.58% |
| 50-Day Moving Average | 1,249.01 |
| 200-Day Moving Average | 1,279.42 |
| Relative Strength Index (RSI) | 47.32 |
| Average Volume (20 Days) | 113,084 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Biotech had revenue of INR 10.55 billion and earned 2.61 billion in profits. Earnings per share was 24.94.
| Revenue | 10.55B |
| Gross Profit | 6.77B |
| Operating Income | 3.04B |
| Pretax Income | 3.45B |
| Net Income | 2.61B |
| EBITDA | 3.77B |
| EBIT | 3.04B |
| Earnings Per Share (EPS) | 24.94 |
Balance Sheet
The company has 4.32 billion in cash and 23.16 million in debt, with a net cash position of 4.30 billion or 41.06 per share.
| Cash & Cash Equivalents | 4.32B |
| Total Debt | 23.16M |
| Net Cash | 4.30B |
| Net Cash Per Share | 41.06 |
| Equity (Book Value) | 20.15B |
| Book Value Per Share | 192.81 |
| Working Capital | 10.81B |
Cash Flow
In the last 12 months, operating cash flow was 2.67 billion and capital expenditures -951.51 million, giving a free cash flow of 1.72 billion.
| Operating Cash Flow | 2.67B |
| Capital Expenditures | -951.51M |
| Depreciation & Amortization | 725.89M |
| Net Borrowing | -6.54M |
| Free Cash Flow | 1.72B |
| FCF Per Share | 16.42 |
Margins
Gross margin is 64.14%, with operating and profit margins of 28.85% and 24.73%.
| Gross Margin | 64.14% |
| Operating Margin | 28.85% |
| Pretax Margin | 32.67% |
| Profit Margin | 24.73% |
| EBITDA Margin | 35.73% |
| EBIT Margin | 28.85% |
| FCF Margin | 16.28% |
Dividends & Yields
This stock pays an annual dividend of 7.55, which amounts to a dividend yield of 0.57%.
| Dividend Per Share | 7.55 |
| Dividend Yield | 0.57% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 42.90% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.57% |
| Earnings Yield | 1.94% |
| FCF Yield | 1.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Concord Biotech is 1,216.00, which is -4.63% lower than the current price. The consensus rating is "Buy".
| Price Target | 1,216.00 |
| Price Target Difference | -4.63% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 18.09% |
| EPS Growth Forecast (3Y) | 21.83% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Concord Biotech has an Altman Z-Score of 46.22 and a Piotroski F-Score of 6.
| Altman Z-Score | 46.22 |
| Piotroski F-Score | 6 |